García-Minamy JI, Vargas-Ayala G, Hernández-Barrera JM, Narváez-Rivera JL, Ángeles-Márquez M, Rivera-Rangel RM, Morales-Santaella AL, Vázquez-Aguirre NA

Language: Spanish
References: 21
Page: 759-765
PDF size: 225.90 Kb.

ABSTRACT

Background: Peritonitis is the inflammation of the peritoneal membrane caused by an infection of the peritoneal cavity, usually by bacteria. Morbidity and mortality can be high. Empirical treatment is based on the administration of broad-spectrum antibiotics covering both grampositive and gramnegative bacteria.
Objective: To determine if the leukocyte/neutrophil index is related to an adequate response to empirical antibiotic treatment in patients with peritonitis associated with peritoneal dialysis.
Material and Method: Cohort study (longitudinal, prospective, observational and analytical) was done including patients from the General Hospital of Ticoman, Xoco and Tlahuac of the Ministry of Health of Mexico City, with a diagnosis of peritonitis associated with peritoneal dialysis. It was performed in all cytochemical patients with dialysis fluid at admission, and a second sample was taken after five days of empirical treatment, and a leukocyte/neutrophil dialysis fluid index was determined. Statistical analysis was performed using the SPSS 20 program.
Results: Twenty-eight individuals with a diagnosis of peritonitis associated with peritoneal dialysis catheter participated, with an average age of 44.1 years; half being men. A statistically significant association (p ‹ .001) was found between the leukocyte/ neutrophil index ‹ 1.2 and the presence of adequate treatment response.
Conclusions: In our study population the leukocyte/neutrophil index is a good predictor of response to antibiotic treatment in peritonitis associated with peritoneal dialysis.

REFERENCES

1. Boudville N, Kemp A, Clayton P, et al. Recent peritonitis associates with mortality among patients treated with peritoneal dialysis. J Am Soc Nephrol 2012 May 24. http:// dx.doi.org/10.1681/ASN.2011121135.

2. Kim Y, Song YR, Kim JK, Kim HJ, Kim S, Kim SG. Use of a new connector decreases peritoneal dialysis-related peritonitis. Perit Dial Int 2014; 34 (1): 128-30. Doi: 10.3747/pdi.2012.0032

3. Li PK, Szeto CC, Piraino B, et al. Peritoneal dialysis-related infections recommendations: 2010 Update. Perit Dial Int 2010; 30 (4): 393-423. doi: 10.3747/pdi.2010.00049

4. Montenegro J, Molina A, Rodríguez-Palomares JR y col. Guías de práctica clínica en diálisis peritoneal. Guías SEN. Peritonitis en Diálisis Peritoneal. Nefrologia 2006; 26 (Suppl. 4): 115131

5. Fernández-Perpén A, Pérez-Lozano ML, Bajo MA, et al. Influence of bicarbonate/low-GDP peritoneal dialysis fluid (Bicavera) on in vitro and ex vivo epithelial-to-mesenchymal transition of mesothelial cells. Perit Dial Int 2012; 32(3): 292-304. doi: 10.3747/pdi.2010.00315

6. Lai KN, Lam MF, Leung JCK, et al. A study of clinical and biochemical profile of peritoneal dialysis fluid low in glucose degradation products. Perit Dial Int 2012; 32 (3): 280-291. doi: 10.3747/pdi.2010.00176

7. Wiggins KJ, Craig JC, Johnson DW, Strippoli GFM. Treatment for peritoneal dialysis-associated peritonitis (Review) Cochrane Database Syst Rev 2008, 23 (1): CD005284. https:// doi.org/10.1002/14651858.CD005284.pub3

8. Montenegro J. Peritonitis bacteriana. Capítulo XVI, páginas En: Tratado de Diálisis Peritoneal. Montenegro J, Correa Rotter R, Riella MC, editores. Barcelona: Elsevier, 2009; 283-320.

9. Rosman JB, Johnson DW. Enterococcal peritonitis in peritoneal dialysis: the danger from within? Perit Dial Int 2011 Sep-Oct;31(5):518-21.

10. Miles R, Hawley CM, McDonald SP, et al. Predictors and outcomes of fungal peritonitis in peritoneal dialysis patients. Kidney Int 2009; 76: 622-8. doi: 10.1038/ ki.2009.202

11. Grassmann A, Gioberges S, Moeller S, Brown G. ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant 2005; 20: 2587-2593. doi: 10.1093/ndt/gfi159

12. Li PK, Szeto CC, Piraino B, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment. Perit Dial Int 2016; 36: 481-508.

13. Mujais S. Microbiology and outcomes of peritonitis in North America. Kidney Int. 2006;70:S55-S62.

14. Ghali JR, Bannister KM, Brown FG, et al. Microbiology and outcomes of peritonitis in Australian peritoneal dialysis patients. Perit Dial Int 2011; 31: 651-662. oi: 10.1038/ sj.ki.5001916.

15. Beiber SD, Anderson AE, Mehrota R. Diagnostic testing for peritonitis in patients undergoing peritoneal dialysis. Semin Dial 2014; 27: 602-606. doi: 10.1111/sdi.12270

16. Figueiredo AE, Bernardini J, Bowes E, et al. A syllabus for teaching peritoneal dialysis patients and caregivers. Perit Dial Int 2016; 36: 592-605. doi: 10.3747/pdi.2015.00277

17. Piraino B, Bernardini J, Brown E, et al. ISPD position statement on reducing the risks of peritoneal dialysis-related infections. Perit Dial Int 2011; 31: 614-630. doi: 10.3747/ pdi.2011.00057

18. Strippoli GF, Tong A, Johnson D, Schena FP, Craig JC. Antimicrobial agents to prevent peritonitis in peritoneal dialysis: a systematic review of randomized controlled trials. Am J Kidney Dis 2004; 44: 591-603.

19. Xu G, Tu W, Xu C. Mupirocin for preventing exit site infection and peritonitis in patients undergoing peritoneal dialysis. Nephrol Dial Transplant 2009; 25: 587-592. doi: 10.1093/ ndt/gfp411

20. Chen SS, Sheeth H, Piraino B, Bender F. Long-term exit-site gentamicin prophylaxis and gentamicin resistance in a peritoneal dialysis program. Perit Dial Int 2016; 36: 387-389. doi: 10.3747/pdi.2015.00162

21. Pierce DA, Williamson JC, Mauck VS, Russell GB, Palavecino E, Burkart JM. The effect on peritoneal dialysis pathogens of changing topical antibiotic prophylaxis. Perit Dial Int 2011; 32: 525-530. doi: 10.3747/pdi.2011.00183